{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T20:48:18Z","timestamp":1795034898742,"version":"4.10.2"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To evaluate the effects of early administration of Sacubitril\/Valsartan (Sac\/Val) in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention (pPCI).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective, controlled, single-center study randomized 186 ST-segment elevation myocardial infarction patients to one of the following two groups: Sac\/Val group: early administration of Sac\/Val within 24 hours after pPCI; control group: conventional angiotensin-converting enzyme inhibitors (ACEI) application. The creatine Kinase (CK) peak after the surgery, the incidence of acute heart failure during hospitalization, level of NT-proBNP and left ventricular ejection fraction (LVEF) measured by ultrasound before discharge and soluble suppression of tumorigenicity2 (sST2), LVEF, infarct size determined by single photon emission computed tomography (SPECT), readmission rate within 6 months were recorded and compared between two groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Compared to the control group, Sac\/Val could decrease the CK peak and the incidence of acute heart failure after pPCI; the level of NT-proBNP was lower and LVEF was higher before discharge in the Sac\/Val group. After 6 months, the patients who had taken Sac\/Val had a higher LVEF, a smaller infarct size determined by SPECT, lower sST2 and readmission rate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention could benefit from early administration of Sacubitril\/Valsartan, the effect was superior to conventional ACEI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mca.0000000000000955","type":"journal-article","created":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T13:04:53Z","timestamp":1598792693000},"page":"427-431","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":23,"title":["Benefits of early administration of Sacubitril\/Valsartan in patients with ST-elevation myocardial infarction after primary percutaneous coronary intervention"],"prefix":"10.1097","volume":"32","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongbo","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zili","family":"Ke","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoqun","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Edong Healthcare Group, Huangshi, Hubei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,27]]},"reference":[{"key":"R1-20250729","first-page":"637","article-title":"Promoting chest pain center accreditation is an essential way to improve the management of acute myocardial infarction in China.","volume":"42","author":"Huo","year":"2014","journal-title":"Zhonghua Xin Xue Guan Bing ZaZhi"},{"key":"R2-20250729","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ahj.2012.12.005","article-title":"Incidence of heart failure and mortality after acute coronary syndromes.","volume":"165","author":"Kaul","year":"2013","journal-title":"Am Heart J"},{"key":"R3-20250729","doi-asserted-by":"crossref","first-page":"e002460","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460","article-title":"Mortality associated with heart failure after myocardial infarction: a contemporary community.","volume":"9","author":"Gerber","year":"2016","journal-title":"Circ Heart Fail"},{"key":"R4-20250729","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure.","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"R5-20250729","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2016.04.047","article-title":"Influence of sacubitril\/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization.","volume":"68","author":"Desai","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R6-20250729","doi-asserted-by":"crossref","first-page":"e012272","DOI":"10.1161\/JAHA.119.012272","article-title":"Effects of the Angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling: meta-analysis.","volume":"8","author":"Wang","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R7-20250729","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with st-segment elevation of the European Society of Cardiology (ESC).","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"key":"R8-20250729","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jcin.2015.10.035","article-title":"Randomized control of sympathetic drive with continuous intravenous esmolol in patients with acute ST-segment elevation myocardial infarction: the beta-blocker therapy in acute myocardial infarction (BEAT-AMI) trial.","volume":"9","author":"Er","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"R9-20250729","first-page":"366","article-title":"Intramyocardial implantation of autologous bone marrow-derived stem cells combined with coronary artery bypass grafting in patients with ischemic cardiomyopathy: a pilot study.","volume":"16","author":"Antonitsis","year":"2012","journal-title":"Hippokratia"},{"key":"R10-20250729","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2009.08.047","article-title":"Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction.","volume":"55","author":"Weir","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R11-20250729","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCRESAHA.116.303577","article-title":"The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis.","volume":"119","author":"Prabhu","year":"2016","journal-title":"Circ Res"},{"key":"R12-20250729","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.3390\/ijms20102430","article-title":"New approaches in the management of sudden cardiac death in patients with heart failure-targeting the sympathetic nervous system.","volume":"20","author":"Kiuchi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R13-20250729","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00395-018-0668-z","article-title":"Molecular imaging of cardiac remodelling after myocardial infarction.","volume":"113","author":"Curley","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"R14-20250729","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamacardio.2018.3789","article-title":"Bioactive signaling in next-generation pharmacotherapies for heart failure: a review.","volume":"3","author":"Oatmen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"R15-20250729","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"PIONEER-HF Investigators. Angiotensin-neprilysin inhibition in acute decompensated heart failure.","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"R16-20250729","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study.","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R17-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of sacubitril-valsartan vs enalapril on aortic stiffness in patients with heart failure and reduced ejection fraction: a randomized clinical trial.","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"R18-20250729","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal Pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"R19-20250729","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"R20-20250729","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1358\/dot.2017.53.10.2722396","article-title":"Sacubitril and valsartan fixed combination to reduce heart failure events in post-acute myocardial infarction patients.","volume":"53","author":"Zaid Iskandar","year":"2017","journal-title":"Drugs Today (Barc)"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000955","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:08:31Z","timestamp":1753812511000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,27]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000955","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,27]]}}}